This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Roche loses bid to block Natco's drug in Indian patent fight

( March 24, 2025, 16:20 GMT | Official Statement) -- MLex Summary: Swiss pharmaceutical giant F. Hoffmann-La Roche has temporarily lost its patent battle after an Indian court denied its request for an interim injunction against Natco Pharma. In a significant judgment delivered by Delhi High Court Judge Mini Pushkarna, the court allowed the Indian drugmaker Natco Pharma to proceed with its plans to manufacture and distribute a more affordable version of Risdiplam, a crucial medication for Spinal Muscular Atrophy. Pushkarna emphasized that public interest, particularly the urgent need for affordable access to the life-saving treatment for a rare disease, outweighed Roche's immediate claim for patent protection.Delhi High Court order attached:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections